ADALIMUMAB-FKJP | B761154 | MYLAN PHARMS INC
Earliest legal licensure (12-year BPCIA floor)
The 12-year reference-product exclusivity is the non-carveable floor — the earliest FDA could license a biosimilar for any indication. Unverified estimate — derived from the earliest available approval record (Jul. 6, 2020), not an FDA-stated exclusivity date. Shown with lower confidence than a Purple Book value.
Full-label vs. best-skinny biosimilar entry
| Scenario | Date | Status | Controlling |
|---|---|---|---|
| Best-skinny entry (floor) | Jul. 6, 2032 | 5y 11mo remaining | 12-year RPE floor (non-carveable) |
| Full-label entry | Jul. 6, 2032 | 5y 11mo remaining | 12-year RPE floor |
Best-skinny equals full-label — no carveable orphan block runs past the licensure floor.
Marketing-entry ceiling (litigation risk)
Patents do not gate FDA licensure of a biosimilar — FDA licenses biosimilars (full or carved label) without adjudicating any patent. These are a practical marketing-entry ceiling resolved in the § 262(l) patent dance and ordinary litigation. A formulation/compound patent caps practical skinny entry via litigation (Regeneron v. Mylan); a method-of-use patent is carveable and gates nothing.
Latest formulation/compound patent 10792372(composition)· AI-discovered, not Purple-Book-listed · relevance 50/100. This caps practical skinny-label entry; it does not move the licensure floor above.
36 formulation/compound (cap skinny entry) · 3 method-of-use (carveable — gate nothing) · 11 device/diagnostic/manufacturing
| Patent | Class | Expiration | Source |
|---|---|---|---|
| 10792372 | Formulation/compound | Oct. 1, 2040Active | Discovered |
| 10494431 | Other | Nov. 28, 2039Active | Discovered |
| 10183117 | Other | Jan. 17, 2039Active | Discovered |
| 10053720 | Other | Aug. 16, 2038Active | Discovered |
| 10040852 | Formulation/compound | Aug. 2, 2038Active | Discovered |
| 9975948 | Other | May. 17, 2038Active | Discovered |
| 9950066 | Formulation/compound | Apr. 19, 2038Active | Discovered |
| 9915665 | Method-of-use (carveable) | Mar. 8, 2038Active | Discovered |
| 9803009 | Formulation/compound | Oct. 26, 2037Active | Discovered |
| 9775916 | Formulation/compound | Sep. 28, 2037Active | Discovered |
| 9750808 | Formulation/compound | Aug. 31, 2037Active | Discovered |
| 9738714 | Formulation/compound | Aug. 17, 2037Active | Discovered |
| 9732152 | Formulation/compound | Aug. 10, 2037Active | Discovered |
| 9598667 | Other | Mar. 16, 2037Active | Discovered |
| 9550986 | Method-of-use (carveable) | Jan. 19, 2037Active | Discovered |
Showing 15 of 50 patents (latest expirations).
Approved Biosimilars
Disclaimer: Identifying an available carve-out is not a prediction that FDA will approve the particular carved label, nor that marketing it is free of infringement risk. For biologics, availability turns on exclusivities, not patents: FDA licenses a biosimilar (full or carved label) without adjudicating any patent, and patent disputes run through the § 262(l) patent dance and ordinary litigation, outside this availability view.
Top 50 of 54 AI-discovered patents by relevance.
No patent or exclusivity listings for this strength.